1.18 小核酸药物研究线上沙龙
小核酸作为一个制药平台技术的发展，与抗体产业的发展有很多相似之处。如果把小核酸药物对标到抗体药物发展进程中，目前可能正处于抗体药物世纪初的产业发展水平：关键技术已经突破，重磅品种开始出现，产业上即将进入爆发性发展时期。核酸药物展示出颠覆性技术的特质，尤其是可能会改变慢性病的治疗理念和策略，未来十年小核酸药物很可能后来居上，形成千亿美元规模的市场。
疾病动物模型是生物医药研究和产业发展不可或缺的支撑条件，好的疾病模型既要与人类疾病相比具有发病同源性、表型一致性、药物治疗预见性，同时又要具有造模易行性、重现性与经济性等特点，在核酸药物临床前研究中仍有很多未被满足的动物模型的需求。
基于此，我们特别邀请了复旦大学生物医学研究院于文强教授，成都先导研发化学中心高级总监陈锦森博士，与南模生物工业客户部总监朱海燕博士一道，举办一场线上学术沙龙，与大家共同探讨小核酸药物发现及临床前研究的相关议题。本次线上沙龙将于今天下午6：30准时开始，扫描文末二维码或点击“阅读原文”均可预约，欢迎大家前来交流讨论。
你也可能感兴趣
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
查看SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
查看At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
查看
